Dr. Babak B. Abrishami, D.O.
Pulmonology (Pulmonary Disease Physician)
1300 N Vermont Ave, Suite 902
Los Angeles, CA 90027
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 663
Licensed in California since 2000, according to the Osteopathic Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
CA license 20A7450 (first issued 2000; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hollywood Presbyterian Medical Center Los Angeles, CA
Medical groups
- Los Angeles Lung Center A Professional Medical Corp (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 663
- Services billed
- 7,565
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 1,319 | 186 |
| Critical care, first 30-74 minutes | 1,134 | 206 |
| Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | 620 | 41 |
| Established patient office or other outpatient visit, 30-39 minutes | 339 | 157 |
| Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | 242 | 44 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 236 | 206 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 132 | 119 |
| Test to determine lung volumes using sensors | 132 | 119 |
| Test to examine how well the lungs exchange gases | 131 | 118 |
| Established patient office or other outpatient visit, 20-29 minutes | 125 | 102 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Los Angeles, CA | 170 |
| Ipratropium-Albuterol (ipratropium/albuterol sulfate) Other prescribers in Los Angeles, CA | 135 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Los Angeles, CA | 106 |
| Famotidine Other prescribers in Los Angeles, CA | 55 |
| Levetiracetam Other prescribers in Los Angeles, CA | 53 |
| Levothyroxine Sodium Other prescribers in Los Angeles, CA | 48 |
| Atorvastatin Calcium Other prescribers in Los Angeles, CA | 41 |
| Chlorhexidine Gluconate Other prescribers in Los Angeles, CA | 40 |
| Ventolin Hfa (albuterol sulfate) Other prescribers in Los Angeles, CA | 35 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Los Angeles, CA | 31 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 11 payments worth $186 in total to this clinician.
| Baxter Healthcare | $65.38 |
|---|---|
| GlaxoSmithKline, LLC. | $50.77 |
| Electromed, Inc. | $42.85 |
| AstraZeneca Pharmaceuticals LP | $26.86 |
| Food and Beverage | $186 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $1,239 in research payments for these studies, mostly to the institutions running them.
- A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.